Cerus Highlights INTERCEPT Blood System Innovations at ISBT Congress — Cerus Corporation

Event summary

Cerus Corporation will present new evidence and innovations for the INTERCEPT Blood System at the 39th International ISBT Congress in Kuala Lumpur from June 20–24, 2026.
Key presentations include real-world data from Asia, focusing on operational efficiency and extended platelet shelf-life.
Abstracts highlight reduced processing times with the LED-based INT200 illuminator and bacterial contamination risks in platelet components in China.
Cerus will host a lunch symposium on pathogen inactivation strategies in transfusion medicine.

The big picture

Cerus is positioning the INTERCEPT Blood System as a critical tool for enhancing blood safety and operational efficiency in transfusion medicine. The focus on real-world evidence from Asia underscores the strategic importance of expanding in high-growth markets. The company’s emphasis on pathogen inactivation aligns with broader industry trends toward proactive risk management in blood supply chains.

What we're watching

Regulatory Progress: The pace at which the INTERCEPT red blood cell system advances through regulatory review in Europe and late-stage clinical development in the U.S.
Market Expansion: Whether Cerus can sustain growth in Asia, particularly in large transfusion markets like China, by addressing bacterial contamination risks.
Operational Efficiency: How reduced processing times with the LED-based INT200 illuminator will impact adoption rates among blood centers globally.